StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)

Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%

Gilead Sciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Gilead Sciences's revenue for the twelve months ending Sep 30, 2026 was $30.99B, up 6.5% year over year. For fiscal 2025 it was $29.44B, up 2.4% from the year before. Over ten years it grew -1.0% a year on average. The highest annual figure on record is $32.64B in fiscal 2015.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.44B+2.4%
FY2024Dec 31, 2024$28.75B+6.0%
FY2023Dec 31, 2023$27.12B-0.6%
FY2022Dec 31, 2022$27.28B-0.1%
FY2021Dec 31, 2021$27.31B+10.6%
FY2020Dec 31, 2020$24.69B+10.0%
FY2019Dec 31, 2019$22.45B+1.5%
FY2018Dec 31, 2018$22.13B-15.2%
FY2017Dec 31, 2017$26.11B-14.1%
FY2016Dec 31, 2016$30.39B-6.9%
FY2015Dec 31, 2015$32.64B+31.1%
FY2014Dec 31, 2014$24.89B+122.2%
FY2013Dec 31, 2013$11.20B+15.5%
FY2012Dec 31, 2012$9.70B+15.7%
FY2011Dec 31, 2011$8.39B+5.5%
FY2010Dec 31, 2010$7.95B+13.4%
FY2009Dec 31, 2009$7.01B+31.4%
FY2008Dec 31, 2008$5.34B+26.1%
FY2007Dec 31, 2007$4.23B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$8.30B+6.8%
Q2 FY2026Jun 30, 2026$7.80B+10.2%
Q1 FY2026Mar 31, 2026$6.96B+4.4%
Q4 FY2025Dec 31, 2025$7.93B+4.7%
Q3 FY2025Sep 30, 2025$7.77B+3.0%
Q2 FY2025Jun 30, 2025$7.08B+1.8%
Q1 FY2025Mar 31, 2025$6.67B-0.3%
Q4 FY2024Dec 31, 2024$7.57B+6.4%
Q3 FY2024Sep 30, 2024$7.55B+7.0%
Q2 FY2024Jun 30, 2024$6.95B+5.4%
Q1 FY2024Mar 31, 2024$6.69B+5.3%
Q4 FY2023Dec 31, 2023$7.11B-3.7%
Q3 FY2023Sep 30, 2023$7.05B+0.1%
Q2 FY2023Jun 30, 2023$6.60B+5.4%
Q1 FY2023Mar 31, 2023$6.35B-3.6%
Q4 FY2022Dec 31, 2022$7.39B+2.0%
Q3 FY2022Sep 30, 2022$7.04B-5.1%
Q2 FY2022Jun 30, 2022$6.26B+0.7%
Q1 FY2022Mar 31, 2022$6.59B+2.6%
Q4 FY2021Dec 31, 2021$7.24B-2.4%
Q3 FY2021Sep 30, 2021$7.42B+12.8%
Q2 FY2021Jun 30, 2021$6.22B+20.9%
Q1 FY2021Mar 31, 2021$6.42B+15.8%
Q4 FY2020Dec 31, 2020$7.42B+26.2%
Q3 FY2020Sep 30, 2020$6.58B+17.4%
Q2 FY2020Jun 30, 2020$5.14B-9.5%
Q1 FY2020Mar 31, 2020$5.55B+5.1%
Q4 FY2019Dec 31, 2019$5.88B+1.4%
Q3 FY2019Sep 30, 2019$5.60B+0.1%
Q2 FY2019Jun 30, 2019$5.69B+0.7%
Q1 FY2019Mar 31, 2019$5.28B+3.8%
Q4 FY2018Dec 31, 2018$5.80B-2.6%
Q3 FY2018Sep 30, 2018$5.60B-14.1%
Q2 FY2018Jun 30, 2018$5.65B-20.9%
Q1 FY2018Mar 31, 2018$5.09B-21.8%
Q4 FY2017Dec 31, 2017$5.95B-18.7%
Q3 FY2017Sep 30, 2017$6.51B–
Q2 FY2017Jun 30, 2017$7.14B–
Q1 FY2017Mar 31, 2017$6.51B–
Q4 FY2016Dec 31, 2016$7.32B–

More Gilead Sciences figures

See a number that looks wrong?